share_log

EFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW) Short Interest Update

EFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW) Short Interest Update

效應器治療, 公司. (納斯達克:EFTRW) 短期利息更新
Defense World ·  2023/02/01 02:13

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW – Get Rating) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 21,500 shares, an increase of 6.4% from the December 31st total of 20,200 shares. Based on an average trading volume of 14,700 shares, the short-interest ratio is presently 1.5 days.

效應器治療, 公司. (NASDAQ: EFTRW-獲取評級) 看到了一月份短期興趣大幅增加.截至 1 月 15 日,總共有 21,500 股的短期利息,較十二月三十一日共 20,200 股股份增加 6.4%。根據 14,700 股的平均交易量計算,短息比率目前為 1.5 天。

eFFECTOR Therapeutics Trading Down 11.6 %

效應器治療交易下降 11.6%

Shares of NASDAQ EFTRW opened at $0.14 on Wednesday. The firm's fifty day moving average is $0.14 and its two-hundred day moving average is $0.15. eFFECTOR Therapeutics has a 52-week low of $0.04 and a 52-week high of $0.73.

納斯達克外匯交易所的股票在周三 0.14 美元開盤。該公司的五十日移動平均線為 0.14 美元,其兩百日移動平均線為 0.15 美元,效應器治療的價格為 52 周低點 0.04 美元,52 周高點為 0.73 美元。

See Also

另請參閱

  • Get a free copy of the StockNews.com research report on eFFECTOR Therapeutics (EFTRW)
  • Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
  • Dividend King Sysco: Buying On The Dip
  • Is the 1,600% Rise in Genius Group Stock Justified?
  • After Further Review, Investors Liked Exxon Mobil's Earnings
  • Will Caterpillar Dig Its Way To Another Buying Opportunity?
  • 獲取有關效應器治療研究報告的免費副本
  • Verizon 公司, 憲章趨勢在過去一個月較高:他們現在買?
  • 股息國王塞斯科:在下跌的購買
  • 天才集團股票上漲 1,600% 是否合理?
  • 經過進一步審查,投資者喜歡埃克森美孚的收益
  • 卡特彼勒會挖掘其方式到另一個購買機會嗎?

Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

每天接收效應器治療的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Effector 治療和相關公司的最新新聞和分析師評級的簡要每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論